PT-141 (Bremelanotide) and AOD-9604 Stack: When to Pick One Over the Stack

What These Two Peptides Actually Do (and Why the Goals Are Different)

PT-141 and AOD-9604 work on entirely different systems in your body. Understanding that distinction is the fastest way to figure out whether you need one, the other, or both.

PT-141, sold under the brand name Vyleesi, is a melanocortin receptor agonist that acts centrally, meaning it crosses into the brain and activates MC3R and MC4R receptors in the hypothalamus to increase sexual motivation and arousal. It does not act on genital blood flow the way a PDE5 inhibitor does. The desire signal originates in the central nervous system. That is the mechanism the FDA accepted when it approved bremelanotide in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women.

AOD-9604 is a synthetic fragment of human growth hormone, specifically the C-terminal region corresponding to amino acids 176 through 191 of the GH sequence. It was originally developed by Metabolic Pharmaceuticals to isolate the lipolytic effects of GH without the insulin-desensitizing effects of the full GH molecule. Animal studies showed it stimulated fat breakdown and inhibited fat synthesis without raising IGF-1 or affecting blood glucose. It holds FDA GRAS (Generally Recognized as Safe) status as a food additive, but it is not FDA-approved as a drug and has no approved human clinical indication.

The short version: PT-141 is for desire. AOD-9604 is for fat metabolism. Their mechanisms do not overlap.

Where Each Peptide Acts in the Female Body

PT-141 (Bremelanotide): Melanocortin receptors relevant to sexual function sit in the medial preoptic area and the paraventricular nucleus of the hypothalamus. In women, activation of MC4R in these regions appears to increase dopaminergic tone, which drives desire rather than arousal per se. The RECONNECT trials, the Phase 3 program that supported FDA approval, enrolled only premenopausal women, so the central signaling data in estrogen-deficient women is extrapolated, not directly studied. That gap matters if you are perimenopausal or post-menopausal.

AOD-9604: The peptide binds to the beta-3 adrenergic receptor on adipocytes and activates a signaling cascade that promotes lipolysis. Preclinical data in obese mice showed dose-dependent fat reduction without growth-promoting or diabetogenic effects. A small Phase 2 trial in humans (AOD9604-003) did not demonstrate statistically significant weight loss over placebo at 12 weeks, which is an important caveat practitioners who promote this peptide often understate. Human RCT evidence is thin.

Why Women's Physiology Changes the Picture

Estrogen modulates melanocortin signaling. Lower estrogen, as seen in perimenopause and post-menopause, may blunt the central response to PT-141, though no head-to-head trial has compared response by hormonal status. For AOD-9604, female adipose tissue has a higher proportion of alpha-2 adrenergic receptors (which inhibit lipolysis) compared to beta-3 receptors (which promote it), particularly in the gluteal-femoral depot. Whether AOD-9604's beta-3 selectivity overcomes this sex-specific receptor distribution is not established in women's data.

PT-141 Alone: Who This Is Right For

PT-141 on its own is the appropriate choice when your primary complaint is low sexual desire and your body composition goals are being managed separately or are not a current priority.

The FDA-Approved Use Case

The RECONNECT Phase 3 trials enrolled 1,247 premenopausal women with generalized acquired HSDD. Bremelanotide 1.75 mg used on demand produced a statistically significant increase in satisfying sexual events versus placebo (0.5 additional events per month, p < 0.001) and a significant reduction in distress about low desire. These are modest but real numbers. The FDA approved 1.75 mg subcutaneous injection to the abdomen or thigh, administered at least 45 minutes before anticipated sexual activity, no more than once in 24 hours, and no more than approximately eight times per month based on the trial design.

Life-Stage Guidance for PT-141 Alone

Reproductive years (cycling women, not TTC): PT-141 is labeled for this group. If you are using hormonal contraception, no interaction with PT-141 has been identified in the prescribing information, though data on combined oral contraceptive users specifically are limited.

Trying to conceive: PT-141 should not be used while actively trying to conceive. See the pregnancy section below.

Perimenopause: Off-label. The hormonal fluctuation of perimenopause may reduce response, but no trial data confirm this. Some clinicians add low-dose testosterone or optimize estrogen before trying PT-141, on the grounds that melanocortin signaling requires adequate estrogenic priming.

Post-menopause: Also off-label. ACOG and The Menopause Society recommend treating genitourinary syndrome of menopause and optimizing systemic hormone therapy before attributing low desire to central HSDD. PT-141 used without addressing estrogen deficiency may underperform.

AOD-9604 Alone: Who This Is Right For

AOD-9604 alone is the choice when your goal is fat loss, specifically targeting adipose tissue, and sexual desire is not a current concern.

Evidence Baseline

The human evidence is notably weaker than for PT-141. The Phase 2 trial (ClinicalTrials.gov NCT reference available through the NIH registry) did not meet its primary weight-loss endpoint. Practitioner-reported outcomes in compounding contexts suggest some women notice reduced visceral fat accumulation over 12 to 16 week courses, but this is anecdotal. Anyone telling you AOD-9604 has strong RCT support in humans is overstating the data.

Female-Specific Conditions Where AOD-9604 Is Being Explored

PCOS: Women with polycystic ovary syndrome have well-documented adipose dysfunction, increased visceral fat, and insulin resistance. PCOS affects 8-13% of reproductive-age women globally. Some integrative practitioners use AOD-9604 in PCOS as an adjunct to metformin or lifestyle because it theoretically does not worsen insulin sensitivity, unlike full-length GH analogs. There is no PCOS-specific trial of AOD-9604.

Perimenopause and post-menopause: The menopausal transition shifts fat distribution toward visceral and abdominal depots. Visceral adiposity increases cardiovascular and metabolic risk in post-menopausal women. If AOD-9604 preferentially targets adipocyte lipolysis, the theoretical appeal in this population is real. The evidence to support it remains preclinical.

Postpartum: No safety data in the postpartum period or during lactation exist. AOD-9604 should not be used while breastfeeding. See the pregnancy and lactation section.

Life-Stage Dosing Notes for AOD-9604

The most commonly cited research protocol is 250-500 mcg subcutaneous injection in the morning, fasted, to take advantage of the endogenous early-morning GH pulse. Some protocols run 5 days on, 2 days off, over 12 to 16 weeks. These are practitioner-derived protocols, not FDA-validated dosing schedules.

The Stack: PT-141 Plus AOD-9604 Together

The case for stacking these two peptides rests entirely on goal divergence, not combination. Because they act on different receptor systems with no overlapping mechanism, using them together does not create a pharmacological interaction in the traditional sense. You are not amplifying one drug with another. You are simply pursuing two separate goals at the same time using two separate molecules.

A practical framework for deciding whether to stack:

| Goal | PT-141 alone | AOD-9604 alone | Stack | |---|---|---|---| | Low libido only | Yes | No | No | | Fat loss only | No | Yes | No | | Low libido AND fat loss | No | No | Yes, if both goals are active | | Perimenopausal with both complaints | Consider with HRT optimization first | Consider | Consider after HRT baseline is set | | Post-menopausal | Off-label, after GSM/HRT addressed | Off-label | Off-label; caution | | Trying to conceive | Contraindicated | No safety data; avoid | Contraindicated | | Pregnant or breastfeeding | Contraindicated | Contraindicated | Contraindicated |

Why the Stack Does Not Add Nausea Risk Multiplicatively

PT-141's main side effect is nausea, occurring in approximately 40% of women in the RECONNECT trials, typically within one hour of injection and resolving within 12 hours. AOD-9604 at standard doses does not produce significant nausea in reported use. Stacking them does not appear to compound nausea risk provided you separate injections temporally. A common approach is to administer AOD-9604 in the morning fasted and PT-141 in the evening before anticipated activity, giving several hours of separation. This also helps you attribute any nausea correctly.

What No One Can Tell You About the Stack

No randomized controlled trial has studied PT-141 and AOD-9604 together. No pharmacokinetic interaction study exists. No safety signal specific to the combination has been identified, but absence of a signal is not the same as confirmed safety. If you experience unexpected symptoms while using both peptides, you have no trial data to help distinguish which one is responsible without stopping them individually.

Pregnancy, Lactation, and Contraception: Required Reading

PT-141 (Bremelanotide):

The FDA prescribing label for Vyleesi states that animal reproductive studies showed fetal harm at doses above the human therapeutic dose. The label advises women to perform a pregnancy test before each use and to discontinue immediately if pregnancy is confirmed. The label does not assign a formal A/B/C/D/X category (these were retired by the FDA in 2015), but the human data are insufficient to establish safety in pregnancy.

Because PT-141 is used on demand for sexual activity, there is an inherent pregnancy exposure risk if contraception is not reliable. Women who are sexually active and not using effective contraception should not use PT-141.

Lactation data are absent. Bremelanotide's molecular weight suggests it could transfer into breast milk, but no human lactation studies have been conducted. The FDA label advises against use while breastfeeding.

AOD-9604:

No human pregnancy or lactation data exist. Animal reproductive toxicity studies have not been published in the peer-reviewed literature for this fragment in isolation. Given the complete absence of safety data, AOD-9604 should be avoided during pregnancy, while trying to conceive, and during breastfeeding. This is not a controversial clinical position. It is a basic precautionary standard.

Contraception requirement for the stack:

If you are using PT-141 and are of reproductive potential, you need effective contraception. If you are also using AOD-9604, the same applies for the same reason: both are contraindicated in pregnancy, and neither should be your reason to delay establishing reliable birth control.

Who This Stack Is Not Right For

Some situations call for a clear "no" or "not yet."

Not right for you if:

• You are pregnant, trying to conceive, or breastfeeding (see above)
• Your low libido has a treatable hormonal cause you have not yet addressed. Low testosterone, undertreated hypothyroidism, and estrogen deficiency all suppress desire. Adding PT-141 before optimizing these is putting the cart before the horse.
• You have cardiovascular disease or uncontrolled hypertension. PT-141 produces a transient mean blood pressure increase of approximately 6 mmHg systolic and 4 mmHg diastolic, peaking around 12 hours post-dose. This is a real concern.
• You are taking medications that cause orthostatic hypotension. The transient BP changes from PT-141 can interact unpredictably.
• You have active malignancy or a history of hormone-sensitive cancer. Melanocortin receptor activation and GH-pathway peptides both warrant caution, though AOD-9604's GH effects are reported to be minimal.
• You are under 18. No pediatric data exist for either peptide.

How to Structure a Protocol if Your Clinician Approves the Stack

The following represents practitioner-derived protocols circulating in the compounding and peptide medicine community. This is not an FDA-approved protocol. Verify with a licensed provider before proceeding.

AOD-9604 Timing

Morning injection of 250-300 mcg subcutaneous to the abdomen, fasted, 30 minutes before eating. Run for 12 weeks, then reassess with body composition testing (DEXA preferred over BMI alone, particularly in women where fat redistribution patterns matter more than total weight).

PT-141 Timing

1.75 mg subcutaneous 45 minutes to one hour before anticipated sexual activity. Use no more than once in 24 hours. If nausea is a problem at 1.75 mg, some compounding pharmacies supply 1.0 mg doses for titration, though this is off-label relative to the FDA-approved 1.75 mg dose.

Tracking Outcomes

For AOD-9604: waist circumference, DEXA-measured visceral fat area, and fasting metabolic markers at baseline and 12 weeks.

For PT-141: a validated patient-reported outcome measure such as the Female Sexual Function Index (FSFI) at baseline and after eight to twelve uses. The FSFI desire subscale is the specific domain PT-141 targets.

Evidence Gaps: What We Do Not Know for Women

Women have historically been underrepresented in peptide pharmacology research. Here is what is directly studied versus extrapolated for this stack:

Directly studied in women (PT-141): Phase 2 and Phase 3 RECONNECT trials enrolled only premenopausal women. FSFI outcomes, nausea incidence, and BP effects are known from this population.

Extrapolated for women (PT-141): Response in perimenopause and post-menopause, interaction with hormonal contraception beyond what is in the label, effect on HSDD secondary to antidepressants (common in women of reproductive age), and long-term use beyond the trial durations.

Extrapolated for women (AOD-9604): Virtually everything. The weight-loss Phase 2 data enrolled mixed-sex cohorts and were not powered for sex-specific subgroup analysis. Female adipose biology differs substantially from male adipose biology in receptor distribution, hormonal responsiveness, and regional fat depot behavior. Assuming male-derived AOD-9604 preclinical data apply directly to women is a significant extrapolation.

Unknown for the stack: Everything. There are no published human studies on the combination of bremelanotide and AOD-9604.

This honesty is not meant to dissuade you. It is meant to help you weigh a decision with accurate information rather than marketing language.

Comparing PT-141 and AOD-9604 to Alternatives

Before committing to either peptide or the stack, it is worth knowing what else exists in the same clinical neighborhood.

For HSDD: Flibanserin (Addyi) is the other FDA-approved option for premenopausal HSDD. It is a daily oral medication that modulates serotonin and dopamine. Its interaction with alcohol is a meaningful safety concern. Some clinicians prefer PT-141 for on-demand use and flibanserin for women who want a standing daily treatment. Off-label testosterone therapy is also used for HSDD in post-menopausal women and is supported by evidence summarized in The Menopause Society's position statement.

For fat loss: GLP-1 receptor agonists (semaglutide, tirzepatide) have substantially stronger RCT evidence for fat loss in women than AOD-9604. The SURMOUNT-1 trial showed tirzepatide produced a mean 22.5% body weight reduction at 72 weeks in adults with obesity. That is a different order of magnitude from anything shown with AOD-9604. If your primary goal is meaningful fat reduction, a GLP-1 agonist is likely to produce a larger and better-documented effect.

The reason some women still consider AOD-9604 alongside or instead of GLP-1s includes: lower cost, absence of GI side effects that characterize GLP-1s, and the theoretical specificity for fat tissue without muscle loss. Whether these advantages are real in women's bodies remains unproven.